Researchers from the Montreal Cancer Institute, Meriem Messaoudene, Dr. Bertrand Routy, and their team, have published a new study in the journal Nature Communications. They demonstrated that DAV132, an absorbent molecule targeting the colon, offers a promising solution by protecting against antibiotic-induced dysbiosis, which is a negative prognostic factor in cancer patients receiving immune checkpoint inhibitors.
The team showed, in a randomized clinical trial involving 148 healthy volunteers, that DAV132, taken with antibiotics, preserves the diversity of beneficial bacteria treated with different antibiotics. Additionally, fecal microbiota transplants in avatar mice showed that DAV132 was able to maintain the response to immune checkpoint inhibitors. This discovery could improve the care of cancer patients receiving antibiotics.
Link to the publication: https://www.nature.com/articles/s41467-024-52373-8
Other news
